Advertisement

Reduction of heart rate — Really a new concept in treating angina pectoris?

  • Åke Hjalmarson

Summary

Myocardial ischemia causing chest pain in patients with angina pectoris is due to an imbalance between coronary blood flow and myocardial metabolic demand. Heart rate is a major determinant of oxygen consumption and metabolic demand, and drugs known to reduce heart rate, such as β-blockers and some calcium blockers have well established effects in patients with angina pectoris. In addition to its importance as a determinant of oxygen consumption, heart rate is also an independent predictor, both of risk of developing acute myocardial infarction as well as a predictor for later complications including death. Increased heart rate can be due to either increased sympathetic activity and/or reduced parasympathetic activity. Psychosocial stress, an important risk factor for development of coronary artery disease, is characterized by an increase in heart rate and systolic blood pressure. β-blockers and calcium blockers are well established in the therapy of ischemic heart disease, and β-blockers are also known to reduce and prevent infarct development and mortality after myocardial infarction. It seems reasonable to believe that new drugs with specific effects on heart rate, without any influence on contractility, could be useful in the therapy of patients with ischemic heart disease, with symptoms of angina pectoris, as well as with supraventricular tachycardia and congestive heart failure.

Keywords

Acute Myocardial Infarction Calcium Channel Blocker Angina Pectoris High Heart Rate Calcium Blocker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barry WH, Brooker JZ, Alderman EL, Harrison DC (1974) Changes in diastolic stiffness and tone of the left ventricle during angina pectoris. Circulation 49: 255–263PubMedGoogle Scholar
  2. 2.
    Beta-blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247: 1707–1714CrossRefGoogle Scholar
  3. 3.
    Chierchia S, Genosa S, Grazier J J (1987) Beta-blockers for the treatment of angina pectoris, indications in relation to pathophysiological mechanisms. J Cardiovasc Pharmacol 10: 529–533Google Scholar
  4. 4.
    Collin P, Fox KM (1990) Pathophysiology of angina. Lancet i: 94–96CrossRefGoogle Scholar
  5. 5.
    Coronary Drug Project Research Group (1974) Factors influencing long-term prognosis after recovery from myocardial infarction—three-year findings of the Coronary Drug project. J Chron Dist 27: 267–285CrossRefGoogle Scholar
  6. 6.
    Davies PF, Olesen S-P, Clapham DE, Morrel EM, Schoen FJ (1988) Endothelial communication. State of the art lecture. Hypertension 11 (6) part 2: 563–572Google Scholar
  7. 7.
    Frishman WH (1986) Beta adrenergic blockade for the treatment of angina pectoris. In: Weiner D, Frishman WD (eds): Therapy of angina pectoris. New York, Marcel Dekker IncGoogle Scholar
  8. 8.
    Gilpin E, Olshen R, Henning H, Ross J Jr (1983) Risk prediction after myocardial infarction, comparison of three multivariate methodologies. Cardiology 70: 73–84PubMedCrossRefGoogle Scholar
  9. 9.
    Gundersen T, Gottum P, Pedersen T, Kjekshus KJ for the Norwegian Multicenter Study Group (1986) Effect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at rest. Am J Cardiol 58: 20–25PubMedCrossRefGoogle Scholar
  10. 10.
    Held PH, Yusuf S, Furberg DC (1989) Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 299: 1187–1192PubMedCrossRefGoogle Scholar
  11. 11.
    Herlitz J, Hjalmarson A (1986) The role of beta-blockade in the limitation of infarct development. Br Heart J 7: 916–924Google Scholar
  12. 12.
    Hjalmarson Å (1991) Cardioprotection after myocardial infarction. Clin Cardiol. Accepted for publicationGoogle Scholar
  13. 13.
    Hjalmarson Å for the MIAMI Trial Research Project (1985) MIAMI: Metoprolol in Acute Myocardial Infarction. Am J Cardiol 56: 1G–57GCrossRefGoogle Scholar
  14. 14.
    Hjalmarson Å, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65: 547–553PubMedCrossRefGoogle Scholar
  15. 15.
    Hjalmarson A, Herlitz J (1984) The Goteborg Metoprolol Trial in acute myocardial infarction. Am J Cardiol 53: 1D–50DGoogle Scholar
  16. 16.
    Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, Ross J Jr (1989) Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS49 in swine. Circulation 80: 983–993PubMedCrossRefGoogle Scholar
  17. 17.
    Kjekshus J (1987) Heart rate reduction—a mechanism of benefit? Eur Heart J 8 (suppl L): 115–122PubMedGoogle Scholar
  18. 18.
    Madsen EB, Gilpin E, Henning H, Ahnve S, LeWinter M, Ceretto W, Joswig W, Collins D, Pitt W, Ross J Jr (1984) Prediction of late mortality after myocardial infarction from variables measures at different times during hospitalization. Am J Cardiol 53: 47–54PubMedCrossRefGoogle Scholar
  19. 19.
    Maseri A, Chierchia S, Kaski JC (1985) Mixed angina pectoris. Am J Cardiol 56: 30E–33EPubMedCrossRefGoogle Scholar
  20. 20.
    Morris Jr JJ (1990) Mechanisms of ischemia in coronary artery disease: Spontaneou decrease in coronary blood supply. Am Heart J 120: 746–756PubMedCrossRefGoogle Scholar
  21. 21.
    Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP (1988) Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 77 (1): 43–52PubMedCrossRefGoogle Scholar
  22. 22.
    Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807CrossRefGoogle Scholar
  23. 23.
    Packer M (1989) Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Eng 1 J Med 320: 709–718Google Scholar
  24. 24.
    The Beta Blockeer Pooling Project (BBPP) (1988) Subgroup findings from randomized trials in postinfarction patients. Eur Heart J 9: 8–16Google Scholar
  25. 25.
    The Danish Study Group on Verapamil in Myocardial Infarction (1990) Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II—DAVIT II). Am J Cardiol 66: 779–785CrossRefGoogle Scholar
  26. 26.
    Tibblin G, Eriksson C-G, Bjuro T, Georgescu D, Svardsudd C (1975) Heart rate and heart rate variability a risk factor for the development of ischaemic heart disease (IHD) in the “men born in 1913 study”—a ten years follow-up. IRGS Medical Science: Cardiovascular System: Social and Occupational Medicine 3: 95. (abstr)Google Scholar
  27. 27.
    Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323 (1): 27–36PubMedCrossRefGoogle Scholar
  28. 28.
    Waagstein F, Hjalmarson A (1875) Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction. Acta Med Scand 587: 201–208Google Scholar
  29. 29.
    Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G; on behalf of the Advisory Committee (1988) Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY Study. JAMA 259 (13) 1976–1982PubMedCrossRefGoogle Scholar
  30. 30.
    Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM (1989) Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 80: 198–205PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1991

Authors and Affiliations

  • Åke Hjalmarson
    • 1
  1. 1.Division of Cardiology, Department of Medicine I, and Wallenberg LaboratoryUniversity of Göteborg, Sahlgren’s HospitalGöteborgSweden

Personalised recommendations